D798EC00001: A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Objective

Clinical Trial Details

IRB Protocol Number

Pro00077346

Clinical Trial Categories

• Head and Neck Cancer

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org